GI Cancer

‘Momentous’: checkpoint inhibitor combo is new benchmark for first-line therapy in advanced HCC

The first therapy to improve survival beyond sorafenib in advanced liver cancer has bee hailed as a landmark in treatment of the disease. A combination of atezolizumab plus bevacizumab improved survival in patients with unresectable liver cancer compared to treatment with sorafenib, according to an international study across 17 countries including Australia. An open-label, phase ...

Already a member?

Login to keep reading.

© 2021 the limbic